Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuronetics Plans Expanded Marketing For Transcranial Magnetic Stimulation Depression Therapy

This article was originally published in The Gray Sheet

Executive Summary

Despite a recent negative Blue Cross Blue Shield technology assessment, Neuronetics is moving ahead with plans to expand sales and marketing efforts for its NeuroStar transcranial magnetic stimulation therapy for drug-resistant depression.

You may also be interested in...



Research in Brief

Neuronetics releases long-term data on NeuroStar TMS therapy for depression. Bayesian methods confirm stenting matches surgery in patients with unprotected left-main disease. More research briefs.

Reimbursement In Brief

Latest news from the Medicare agency and other payers.

Regulatory News In Brief

User fees to go down next year

Related Content

Topics

UsernamePublicRestriction

Register

OM006145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel